600201: Jinyu Bio-technology Co., Ltd. - Summary | Jitta

Jinyu Bio-technology Co., Ltd.

CHN:600201

Price
CN¥14.59
Loss Chance
49.2%
4.51JITTA SCORE
731.33%Over Jitta Line
Jitta Ranking
101 / 487
1,057 / 5,260
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (48)
Recent Business Performance (74)
Financial Strength (81)
Return to Shareholders (20)
Competitive Advantage (28)
Jitta Signs
Debt LevelLow Long Term Debt
Share RepurchaseEvery Year
Revenue and EarningRevenue decline from 2021-2024
Operating MarginDeclined
Recent Business PerformanceEarning decline 76.79% in the last year
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
4.51
731.33%
3.54
> 1,000%
4.24
> 1,000%
Biotechnology
4.53
53.96%
5.50
138.47%
7.72
18.96%
COMPANY DESCRIPTION
Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine influenza bivalent, porcine reproductive and respiratory syndrome, pseudorabies thermo-stable, porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 baculovirus vector, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine foot and mouth disease bivalent, porcine parvovirus, pseudorabies, haemophilus parasuis trivalent, and porcine circovirus type 2 vaccines. It also provides ruminant vaccines, such as foot and mouth disease trivalent, bovine pasteurella multocida, combined bovine viral diarrhea disease and infectious bovine rhinotracheitis, brucella gene deletion, goat pox, brucellosi, brucellosis, foot and mouth disease bivalent and type O, clostridium chauvoei, lumpy skin disease, combined ovine infectious necrotic hepatitis and braxy, and caprine infectious pleuropneumonia, as well as combined ovine braxy, struck, lamb dysentery, enterotoxaemia, and black disease and clostridium botulinum toxonosis vaccines. In addition, the company offers avian vaccines; rabies vaccines; and PCR and Elisa diagnostic kits. Further, it is involved in manufacturing and sales of veterinary chemical preparations, chemical reagents and auxiliary agents, biological drug preparations, and advanced medical equipment and instruments; biotechnology development, transfer, and consulting services; import and export of goods and technology; and provision of property management services. The company was founded in 1992 and is headquartered in Hohhot, China.